Phenotypes associated with this allele

• Allele Symbol: Mir301^tm1Yoli
• Allele Name: targeted mutation 1, Yong Li
• Allele ID: MGI:5817372
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Mir301^tm1Yoli/Mir301^tm1Yoli	involves: C57BL/6J	MGI:5823079
cx2	Kras^tm3Tyj/Kras^tm3Tyj Mir301^tm1Yoli/Mir301^tm1Yoli	involves: 129S4/SvJae * C57BL/6J	MGI:5823077

Genotype
MGI:5823079

hm1

• Allelic Composition: Mir301^tm1Yoli/Mir301^tm1Yoli
• Genetic Background: involves: C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

decreased tumor incidence ( J:237900 )

decreased incidence of tumors by chemical induction ( J:237900 )

• 25% of mice treated with the carcinogen AOM and DSS develop colitis-associated cancer as compared to 100% incidence in wild-type mice

• in addition, average tumor size and cell proliferation is decreased as compared to wild-type

• mice treated with 3.5% DSS exhibit less body weight loss, and reduced colon shortening, fewer incidences of bloody stool, rectal bleeding and anal prolapse than wild-type mice

• treated mice exhibit less colonic mucosal damage as compared to wild-type

• treated mice have decreased intestinal cell proliferation, decreased levels of IL6, TNFA and IL17, and decreased secretion of IL6, TNFA and IL17 as compared to wild-type

immune system

abnormal response to transplant ( J:237900 )

• mice transplanted with Lewis lung carcinoma cells exhibit smaller tumors than wild-type and decreased proliferation

• decreased tumor growth is observed when mice are transplanted with B16 melanoma cells

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:237900 )

• 25% of mice treated with the carcinogen AOM and DSS develop colitis-associated cancer as compared to 100% incidence in wild-type mice

• in addition, average tumor size and cell proliferation is decreased as compared to wild-type

• mice treated with 3.5% DSS exhibit less body weight loss, and reduced colon shortening, fewer incidences of bloody stool, rectal bleeding and anal prolapse than wild-type mice

• treated mice exhibit less colonic mucosal damage as compared to wild-type

• treated mice have decreased intestinal cell proliferation, decreased levels of IL6, TNFA and IL17, and decreased secretion of IL6, TNFA and IL17 as compared to wild-type

Genotype
MGI:5823077

cx2

• Allelic Composition: Kras^tm3Tyj/Kras^tm3Tyj; Mir301^tm1Yoli/Mir301^tm1Yoli
• Genetic Background: involves: 129S4/SvJae * C57BL/6J

integument

decreased skin tumor incidence ( J:237900 )

• decreased incidence of skin papillomas (7.1% vs 17.6%) as compared to mice homozygous for Kras^tm3Tyj

mortality/aging

premature death ( J:237900 )

• increased survival rates (approx 262 days vs 166 days) as compared to mice homozygous for Kras^tm3Tyj

neoplasm

decreased tumor growth/size ( J:237900 )

• tumors are smaller in size when compared to tumors from mice homozygous for Kras^tm3Tyj

decreased tumor incidence ( J:237900 )

decreased skin tumor incidence ( J:237900 )

• decreased incidence of skin papillomas (7.1% vs 17.6%) as compared to mice homozygous for Kras^tm3Tyj

decreased lymphoma incidence ( J:237900 )

• decreased incidence of thymic lymphomas (21.4% vs 32.3%) as compared to mice homozygous for Kras^tm3Tyj

decreased lung tumor incidence ( J:237900 )

• decrease in number of lung tumors at 18 weeks as compared to mice homozygous for Kras^tm3Tyj although all mice develop lung tumor

• decreased incidence of thymic lymphomas (21.4% vs 32.3%) and skin papillomas (7.1% vs 17.6%)